BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16716128)

  • 21. Metabolic effects of the atypical antipsychotics.
    Wooten J
    South Med J; 2007 Aug; 100(8):771-2. PubMed ID: 17713300
    [No Abstract]   [Full Text] [Related]  

  • 22. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
    Dubois D
    Curr Opin Pediatr; 2005 Apr; 17(2):227-33. PubMed ID: 15800418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical antipsychotics and pituitary neoplasms in the WHO database.
    Doraiswamy PM; Schott G; Star K; Edwards R; Mueller-Oerlinghausen B
    Psychopharmacol Bull; 2007; 40(1):74-6. PubMed ID: 17285098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y; Kim E; You M; Pikalov A; Tran QV
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
    Pathak P; West D; Martin BC; Helm ME; Henderson C
    Psychiatr Serv; 2010 Feb; 61(2):123-9. PubMed ID: 20123816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
    Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucose intolerance with atypical antipsychotics.
    Hedenmalm K; Hägg S; Ståhl M; Mortimer O; Spigset O
    Drug Saf; 2002; 25(15):1107-16. PubMed ID: 12452735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
    Tsuboi T; Bies RR; Suzuki T; Mamo DC; Pollock BG; Graff-Guerrero A; Mimura M; Uchida H
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():178-82. PubMed ID: 23727135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Endocrine side effects among psychiatric patients treated with antipsychotics].
    Kovács L; Kovács G
    Neuropsychopharmacol Hung; 2006 Jun; 8(2):61-6. PubMed ID: 17073213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
    Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
    Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing atypical antipsychotic treatment strategies in the elderly.
    Katz IR
    J Am Geriatr Soc; 2004 Dec; 52(12 Suppl):S272-7. PubMed ID: 15541168
    [No Abstract]   [Full Text] [Related]  

  • 37. The value of atypical antipsychotics in the treatment of schizophrenia.
    Jessen LM
    Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
    [No Abstract]   [Full Text] [Related]  

  • 38. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
    Wang PS; Schneeweiss S; Setoguchi S; Patrick A; Avorn J; Mogun H; Choudhry NK; Brookhart MA
    J Clin Psychopharmacol; 2007 Dec; 27(6):707-10. PubMed ID: 18004143
    [No Abstract]   [Full Text] [Related]  

  • 40. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
    Keller R; Mongini F
    Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.